argenx SE

argxNASDAQModerate Risk

FcRn antibody technology

Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

AutoimmuneNeurology

Market cap

Large cap

Cash position

$3.2B as of Q4 2025

Q4 2025 — 3 quarters ago

Revenue status

early revenue

Pipeline assets

3 programs

Trade argx commission-free on Webullvia Webull · Affiliate

What does argenx SE do?

argenx developed Vyvgart which lowers harmful antibody levels by blocking FcRn receptor. Approved for myasthenia gravis and tested for many autoimmune diseases. One of the most promising platform stories in biotech with over $3B cash. Key risk is competition from other FcRn drugs.

What to watch

1

CIDP Phase 3 data mid-2026

2

Vyvgart revenue growth

3

UCB competitive data

4

ITP results 2026

5

International launch

Pipeline

DrugIndicationPhaseExpected data
VyvgartGeneralized Myasthenia GravisApprovedNot disclosed▼
Vyvgart HytruloCIDPPhase 3Not disclosed▼
EmpasiprubartKidney transplant rejectionPhase 2Not disclosed▼

Investment thesis

Bull case

Dominant FcRn franchise with Vyvgart blockbuster. Same drug tested across CIDP ITP pemphigus myositis. Strong $3.2B cash. Peak sales exceed $8B. Platform validated across diseases.

Bear case

Intense FcRn competition. Label expansion failures possible. Pricing pressure. High valuation. Manufacturing complexity.

Key upcoming catalysts

No upcoming catalyst for argenx SE has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.

Risk factors

⚠

FcRn competition

⚠

Label expansion failures

⚠

Pricing pushback

⚠

Manufacturing challenges

⚠

Market access

Chart argx on TradingView — used by 30M+ tradersvia TradingView · Affiliate

Comparable companies

UCBBYIMVTALNYBMRN

Financial snapshot

These figures are drafted by our AI pipeline, not read from SEC filings. Confirm anything you would act on against the company's latest 10-Q or 10-K.

Cash

$3.2B as of Q4 2025

Q4 2025 — 3 quarters ago

Quarterly burn

Approaching breakeven

Cash runway

Not derivable

cash or burn not disclosed as a figure

Revenue

early revenue

Institutional ownership

88%

Source: company profile text. These figures come from the company profile text, not from a filing we have parsed. Check them against the latest 10-Q before relying on them.

These figures are out of date

The cash position cited here is from Q4 2025, roughly 3 quarters ago. The company has almost certainly reported since. Check its latest filing before using any of this.

Sponsored

Get premium argx analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Argenx has 57 Phase 2 or 3 studies on ClinicalTrials.gov: 20 completed, 7 stopped early, 30 ongoing.

20

Completed

7

Stopped early

30

Ongoing

Stopped early

  • UplighTEDPhase 3 · started 2024 · terminated

    Efgartigimod PH20 SC in thyroid eye disease · n=105

    Reason given: The pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged

  • UplighTEDPhase 3 · started 2024 · terminated

    Efgartigimod PH20 SC in thyroid eye disease · n=102

    Reason given: The pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged.

  • POTSPhase 2 · started 2023 · terminated

    Efgartigimod in post-covid postural orthostatic tachycardia syndrome postural orthostatic tachycardia syndrome · n=33

    Reason given: Due to the phase 2 results of the main study (ARGX-113-2104) showing that efgartigimod-treated PC-POTS patients had no clinically meaningful improvement, the decision has been made to terminate this open-label extension study (ARGX-113-2105) study.

  • BALLAD+Phase 3 · started 2023 · terminated

    efgartigimod PH20 SC in bullous pemphigoid · n=64

    Reason given: Sponsor decision

  • NCT05810961Phase 2 · started 2023 · terminated

    efgartigimod IV in membranous nephropathy · n=8

    Reason given: Sponsor decision

  • ADDRESS+Phase 3 · started 2021 · terminated

    efgartigimod PH20 SC in pemphigus vulgaris · n=183

    Reason given: Based on the lack of observed efficacy in the primary study ARGX-113-1904, the sponsor decided to discontinue the open-label extension study.

  • ADVANCE2Phase 3 · started 2020 · withdrawn

    efgartigimod in primary immune thrombocytopenia (itp) · n=0

    Reason given: The ARGX-113-1908 study will be replaced by a similar design with a subcutaneous formulation (ARGX-113-2004)

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-13 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.